期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Long-term experience with debulking surgery in extensive hepatic alveolar echinococcosis:A case series and literature review
1
作者 Mohsen Aliakbarian Marcello Di Martino Sara Saeidi 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2022年第10期468-473,共6页
Objective:To assess the role of debulking surgery in extensive hepatic alveolar echinococcosis(HAE).Methods:Five cases of extensive HAE undergoing debulking surgery with their long-term follow-ups were reported.Additi... Objective:To assess the role of debulking surgery in extensive hepatic alveolar echinococcosis(HAE).Methods:Five cases of extensive HAE undergoing debulking surgery with their long-term follow-ups were reported.Additionally,a systematic review was carried out.Results:The average age of patients in the study was(50.8±17.1)years(range 36 to 77 years).Three cases were female.The median follow-up period was 61 months(range 12 to 84 months).Left liver resections were performed in 2 cases and right hemihepatectomies were undertaken in 2 cases.Two patients(cases 2 and 4)developed early surgical complications,while one of them(case 4)who suffered from the recurrent sub-hepatic abscess died at 12 months postoperatively.Conclusions:This study highlights the importance of debulking surgery for the management of complex symptomatic HAE lesions in patients with no curative option available. 展开更多
关键词 Alveolar echinococcosis debulking surgery REDUCTION PALLIATIVE Echinoccocosis multilocularis Case series
下载PDF
Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors:a comparative study
2
作者 Xi-Tai Huang Jin-Zhao Xie +5 位作者 Liu-Hua Chen Jian-Peng Cai Wei Chen Li-Jian Liang Ning Zhang Xiao-Yu Yin 《Gastroenterology Report》 SCIE CSCD 2023年第1期247-253,共7页
Background and objective:The value of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumor(m-PNET)remains poorly defined.This study aimed to evaluate the outcomes of m-PNET... Background and objective:The value of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumor(m-PNET)remains poorly defined.This study aimed to evaluate the outcomes of m-PNET following debulking surgery in our institute.Methods:Patients with well-differentiated m-PNET in our hospital between February 2014 and March 2022 were collected.Clinicopathological and long-term outcomes of patients treated with radical resection,debulking surgery,and conservative therapy were compared retrospectively.Results:Fifty-three patients with well-differentiated m-PNET were reviewed,including 47 patients with unresectable m-PNET(debulking surgery,25;conservative therapy,22)and 6 patients with resectable m-PNET(radical resection).Patients undergoing debulking surgery had a post-operative Clavien–DindoIII complication rate of 16.0%without mortality.The 5-year overall survival(OS)rate of patients treated with debulking surgery was significantly higher than that of those treated with conservative therapy alone(87.5%vs 37.8%,log-rank P=0.022).Besides,the 5-year OS rate of patients treated with debulking surgery was comparable to that of patients with resectable m-PNET undergoing radical resection(87.5%vs 100%,log-rank P=0.724).Conclusions:Patients with unresectable well-differentiated m-PNET who underwent resection had better long-term outcomes than those who received conservative therapy alone.The 5-year OS of patients undergoing debulking surgery and radical resection were comparable.Debulking surgery could be considered for patients with unresectable well-differentiated m-PNET if no contraindication exists. 展开更多
关键词 pancreatic neuroendocrine tumor METASTASIS debulking surgery PROGNOSIS
原文传递
Risk factors of major intraoperative blood loss at primary debulking surgery for ovarian cancer
3
作者 Sha Dou Junchen Chen +3 位作者 Yuanfen Wang Chongyuan Zhu Heng Cui Yi Li 《Gynecology and Obstetrics Clinical Medicine》 2022年第1期9-13,共5页
Objective:The goal of this study was to find the risk factors for major intraoperative blood loss(MBL)of pr imary debulking surgery(PDS)for ovarian cancer.Methods:Patients wi th ovarian cancer who underwent PDS in our... Objective:The goal of this study was to find the risk factors for major intraoperative blood loss(MBL)of pr imary debulking surgery(PDS)for ovarian cancer.Methods:Patients wi th ovarian cancer who underwent PDS in our hospital,from 2010 to 2017,were enrolled.The association between risk factors and MBL was modeled with the use of logisde regr ession.Receiver operating characteristic(ROC)curve analysis was used to determine the predictive value of the logi stic regression model.Results:A total of 346 padients met the inclusion criteria.There were 150 patients with MBL.Tumor stage 3/4(P<0.001),American Society of Aneshesiologists(ASA)score 23(P=0.044),ascites volume≥500 ml(P=0.002),radical or ultra radical surgery(P=0.002),and diabetes(P=0.035)were independent risk factors for MBL in patients with ovarian cancer.The logistic regression combined model of these five factors is more reliable in the prediction of MBL with an area under the ROC curve of 0.729 than the tumor stage(ROC curve=0.645)and surgical complexity(ROC curve=0.568).Conclusion:In padients with ovarian cancer,five risk factors for major intraoperative bleeding were identified.Planned surgical procedures and preoperative risk factors can be used to predict perioperative blood requir ements. 展开更多
关键词 Ovarian cancer Intraoperative blood loss Primary debulking surgery Risk factors
原文传递
Neoadjuvant Chemotherapy Followed by Surgery versus Primary Surgery in Advanced Epithelial Ovarian Cancer: A Review of Outcomes at National Institute of Cancer Research Hospital in Bangladesh
4
作者 Farhana Kalam Shahana Pervin +2 位作者 K. M. Nazmul Islam Joy Johirul Islam Annekathryn Goodman 《Journal of Cancer Therapy》 2021年第11期621-633,共13页
<strong>Introduction:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> This study evaluated ... <strong>Introduction:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> This study evaluated the difference in operative and clinica</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">l outc</span><span style="font-family:Verdana;">omes for patients with advanced ovarian cancer after primary debulking</span><span style="font-family:Verdana;"> surgery (PDS) versus neoadjuvant chemotherapy (NACT) followed by interval debul</span><span><span style="font-family:Verdana;">king surgery (IDS) in Bangladesh. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> Sixty patients with a</span></span><span style="font-family:Verdana;">dvanced epit</span><span style="font-family:Verdana;">helial ovarian cancer presenting to the department of Gynaecologi</span><span style="font-family:Verdana;">cal Oncology at the National Institute of Cancer Research and Hospital were prospectively enrolled. Thirty patients underwent primary debulking surgery and thirty patients received NACT followed by IDS. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> In the PDS and IDS groups respectively, 56.7% and 50% of patients presented with stage IIIC and 67.7% and 56.7% respectively had ser</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">i</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">ous papillary type histopathology. Duration of surgery, amount of blood loss and total hospital stay were significantly lower (p < 0.001) in IDS group than </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">in </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">the PDS group. There was a statistically significant difference in postoperative tumor residuals between IDS and PDS patients. Complete tumor resection (R0) was obtained in 24 (80%) of IDS patients versus 13 (43.3%) PDS patients. In fifteen months of follow-up, 21 (70%) in the PDS group and 5 (16.7%) in the IDS group recurred (</span><span style="font-family:Verdana;">p</span><span style="font-family:Verdana;"> = 0.021). Median progression free survival in PDS patients was twelve months while that of the IDS group was seventeen months. There was one death at 45 days in the PDS group. No other deaths were documented at fifteen months of follow-up. </span><b><span style="font-family:Verdana;">Conclusion</span></b></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">:</span></b></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Interval debulking surgery has a more favorable outcome than primary debulking surgery on progression free survival in advanced ovarian cancer patients </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">and </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">permits a less aggressive surgery to be performed in Bangladesh.</span></span></span> 展开更多
关键词 Neoadjuvant Chemotherapy Interval debulking surgery Primary debulking surgery Cytoreductive surgery Epithelial Ovarian Cancer BANGLADESH
下载PDF
Giant hepatic extra-gastrointestinal stromal tumor treated with cytoreductive surgery and adjuvant systemic therapy:A case report and review of literature 被引量:3
5
作者 Michel Ribeiro Fernandes Caroline Lorenzoni Almeida Ghezzi +6 位作者 Tomaz J M Grezzana-Filho Flávia Heinz Feier Ian Leipnitz Aljamir Duarte Chedid Carlos Thadeu Schmidt Cerski Marcio Fernandes Chedid Cléber RositoPinto Kruel 《World Journal of Gastrointestinal Surgery》 SCIE 2021年第3期315-322,共8页
BACKGROUND Primary extra-gastrointestinal stromal tumors(E-GIST)of the liver are rare.The clinical presentation may range from asymptomatic to bleeding or manifestations of mass effect.Oncologic surgery followed by ad... BACKGROUND Primary extra-gastrointestinal stromal tumors(E-GIST)of the liver are rare.The clinical presentation may range from asymptomatic to bleeding or manifestations of mass effect.Oncologic surgery followed by adjuvant therapy with imatinib is the standard of care.However,under specific circumstances,a cytoreductive approach may represent a therapeutic option.We describe herein the case of an 84-year-old woman who presented with a tender,protruding epigastric mass.Abdominal computed tomography scan revealed a large,heterogeneous mass located across segments III,IV,V,and VIII of the liver.The initial approach was transarterial embolization of the tumor,which elicited no appreciable response.Considering the large size and central location of the tumor and the advanced age of the patient,non-anatomic complete resection was indicated.Due to substantial intraoperative bleeding and hemodynamic instability,only a near-complete resection could be achieved.Histopathology and immunohistochemical staining confirmed the diagnosis of primary E-GIST of the liver.Considering the risk/benefit ratio for therapeutic options,debulking surgery may represent a strategy to control pain and prolong survival.CASE SUMMARY Here,we present a case report of a patient diagnosed with E-GIST primary of the liver,which was indicated a cytoreductive surgery and adjuvant therapy with imatinib.CONCLUSION E-GIST primary of the liver is a rare conditional,the treatment is with systemic therapy and total resection surgery.However,a cytoreductive surgery will be necessary when a complete resection is no possible. 展开更多
关键词 Extra-gastrointestinal stromal tumor Primary gastrointestinal stromal tumor of the liver Cytoreductive surgery debulking surgery Case report
下载PDF
Current surgical management of pancreatic endocrine tumor liver metastases 被引量:5
6
作者 Theodoros E Pavlidis Kyriakos Psarras +2 位作者 Nikolaos G Symeonidis Efstathios T Pavlidis Athanasios K Sakantamis 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2011年第3期243-247,共5页
BACKGROUND: The management of metastatic disease in pancreatic endocrine tumors (PETs) demands a multidisciplinary approach and the cooperation of several medical specialties. The role of surgery is critical, even whe... BACKGROUND: The management of metastatic disease in pancreatic endocrine tumors (PETs) demands a multidisciplinary approach and the cooperation of several medical specialties. The role of surgery is critical, even when a radical excision cannot always be achieved. DATA SOURCES: A PubMed search of relevant articles published up to February 2011 was performed to identify current information about PET liver metastases regarding diagnosis and management, with an emphasis on surgery. RESULTS: The early diagnosis of metastases and their accurate localization, most commonly in the liver, is very important. Surgical options include radical excision, and palliative excision to relieve symptoms in case of failure of medical treatment. The goal of the radical excision is to remove the primary tumor bulk and all liver metastases at the same time, but unfortunately it is not feasible in most cases. Palliative excisions include aggressive tumor debulking surgeries in well-differentiated carcinomas, trying to remove at least 90% of the tumor mass, combined with other additional destructive techniques such as hepatic artery embolization or chemoembolization to treat metastases or chemoembolization to relieve symptoms in cases of rapidly growing tumors. The combination of chemoembolization and systemic chemotherapy results in better response and survival rates. Other local destructive techniques include ethanol injection, cryotherapy and radiofrequency ablation. CONCLUSION: It seems that the current management of PETs can achieve important improvements, even in advanced cases. 展开更多
关键词 pancreatic endocrine tumors pancreas islet cell neoplasms neuroendocrine tumors liver metastases surgical management debulking surgery
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部